A consensus has emerged that approval of biosimilars requires both biological and clinical evidence. The ‘comparability exercise’ requires consideration of a wide range of aspects, including analytical and physico-chemical characterisation by several methods, comparative biological assays, comparative immunogenicity assessment, among others. The use of different host cells for the biosimilar product and the comparator in principle is possible.
Approval of biosimilar epoetins: how similar are they?
Biosimilars/Research | Posted 24/09/2010 0 Post your comment
Although required, a clinical programme for a biosimilar should have the primary aim of establishing ‘similarity’ and thus might be abridged compared with full clinical development of a new drug. The extent of studies required depends on the complexity of the product, its mode of action, its toxicity, the possible clinical effect of immunogenicity and the comparability of the response in different populations. See Table 1.
Table 1: Biosimilar erythropoietins approved in the EU in 2007
The high standards manufacturers of follow-up biologics have to meet require extensive investment in product testing, production and marketing. Consequently, the cost of protein drugs will continue to be relatively high.
Related article
Biosimilar epoetins: how similar are they?
Reference
Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004;10(3):243-7.
News
First denosumab biosimilars approved in Canada and the US
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
General
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Insurer perspective on increasing biosimilar uptake in Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
ANVISA's role in biosimilar medicine regulation and innovation promotion
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Comments (0)
Post your comment